Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Cambridge,
MA 02142
United States - Map
Phone: 617-492-5554
Fax: 617-492-5664
Web Site: http://www.molecularinsight.com
| Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003. Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. John W. Babich Ph.D., 51
Founder, Chief Scientific Officer, Exec. VP, Pres of R&D |
$
341.00K |
$
0 | Mr. Norman D. LaFrance M.D., FACP, FACNP, 61
Chief Medical Officer and Sr. VP of Clinical Devel. |
$
335.00K |
$
0 | Mr. James A. Wachholz , 55
VP of Regulatory Affairs & Quality Assurance |
N/A
| N/A | Mr. Daniel L. Peters , 57
Chief Exec. Officer, Pres, Chief Operating Officer |
N/A
| N/A | Mr. Charles H. Abdalian Jr., 57
Chief Financial Officer and VP of Fin. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
0.02 (0.60%) 
Profile
